NCT06701812 · H. Lee Moffitt Cancer Center and Research Institute
Digoxin Medulloblastoma Study
What this study is about
The purpose of this study is to evaluate the effectiveness of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
View original scientific description
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Interventions
DRUG
Digoxin
2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.
Primary outcome measures
Progression Free Survival at 4 months (PFS4)
Time frame: 4 months
Proportion of patients with progression free survival at 4 months after initiation of treatment.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Patients must be age \>12 months and \<30 years at the time of enrollment.
- Patients must have relapsed non-WNT, non-SHH medulloblastoma confirmed by a CAP/CLIA certified assay (such as nanostring or methylation) performed on tissue from diagnosis or relapse.
- Patients must have received at least one prior course of chemotherapy for their medulloblastoma. They must also have received irradiation.
- Prior therapy: Therapy may not have been received more recently than the timeframes defined below: Craniospinal radiotherapy: At least 3 months have elapsed since prior craniospinal radiotherapy (at doses ≥ 18 Gy). Local radiotherapy: At least 3 months since prior local radiotherapy to primary tumor. Focal radiotherapy: At least 2 weeks since prior focal radiotherapy to symptomatic metastatic sites. Myelosuppressive chemotherapy and/or immunotherapy and/or biologics: More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas), immunotherapy
Where
- Birmingham, Alabama
- Little Rock, Arkansas
- Hartford, Connecticut
- Washington D.C., District of Columbia
- Jacksonville, Florida
- Miami, Florida
- St. Petersburg, Florida
- Tampa, Florida
- Baltimore, Maryland
- St Louis, Missouri
- The Bronx, New York
- Chapel Hill, North Carolina
And 3 more locations — see the full list below.
Collaborators
National Pediatric Cancer Foundation
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 7, 2026 · Source of record for eligibility and locations